ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1748

Fracture Incidence Rates in Persons with Rheumatoid Arthritis by Disease Activity Level

Rachel Elam1, Emma Kersey2, Jing Li3, Gabriela Schmajuk4 and Laura Carbone5, 1Augusta University, Evans, GA, 2University of California San Francisco, San Francisco, CA, 3University of California, San Francisco, San Francisco, CA, 4UCSF / SFVA, San Francisco, CA, 5Augusta University, Augusta, GA

Meeting: ACR Convergence 2024

Keywords: Disease Activity, Epidemiology, Fracture, osteoporosis, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Abstracts: RA – Diagnosis, Manifestations, & Outcomes III: Best Day (RA Subpopulations)

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Fracture incidence rates (IRs) are higher in men and women with rheumatoid arthritis (RA) than those without RA, especially for those with higher RA disease activity. In persons with RA worldwide, the IR per 1,000 person-years (PYs) of any fragility fracture is 15.3 (95% confidence interval (CI): 10.4-22.5) and the IR of hip fracture is 4.3 (95% CI: 2.3-8.3), but IRs for modern U.S. cohorts have not been described. This study describes fracture IRs and incidence rate ratios (IRRs) in persons with RA in the U.S. by disease activity level.

Methods: We conducted a retrospective cohort study (2016-2018) using Rheumatology Informatics System for Effectiveness (RISE) data linked to Medicare claims. RISE is a national, electronic health record-enabled registry of participating rheumatology practices. We included men and women ≥ 65 years old with RA (≥ 2 visits with RA codes ≥ 30 days apart) and required continuous Medicare (Parts A, B) coverage in 2016 and January 2017. RA disease activity was ascertained from the most recent visit prior to 1/1/2017 where disease activity was documented, and categorized as remission, low, moderate, or high, regardless of measure used. Incident hip and major osteoporotic fracture (MOF: first of distal forearm, hip, humerus, or vertebral fracture) were determined using validated case qualifying Medicare claims-based fracture episode definitions. Participants were followed from 1/1/2017 until the first of: incident fracture (hip or MOF, respectively), death, gap in Medicare enrollment (Parts A, B, or D), or end of the study period (12/31/2018). IRs and 95% CIs for hip fracture and MOF overall and stratified by sex and disease activity level were reported. IRRs for disease activity level were estimated by dividing the IR of individuals at each disease activity level by the IR of those in remission, and 95% CIs computed.

Results: Of 29,189 study participants (mean age: 73.7 years, 75% women, 85% White; Table 1), 704 persons (594 women) fractured a hip and 2,425 persons (2,070 women) had a MOF. The overall IR for hip fracture was 12.2 (95% CI: 11.4-13.2) per 1,000 PYs and for MOF was 43.3 (95% CI: 41.6-45.1). The IRs for hip and MOF increased with higher disease activity overall and in women, while in men, this increase was observed only for MOF (Table 2). High disease activity was associated with higher rates of hip fracture (Figure 1). Disease activity above remission was associated with higher rates of MOF (Figure 1).

Conclusion: In persons with RA aged 65 years and older, hip fracture and MOF are more common in patients with RA disease activity above remission, especially those with high disease activity. These findings emphasize the importance of bone health assessments in RA, particularly among those with high disease activity, as the risk of hip fracture and MOF are significantly increased in the following two years.

Supporting image 1

Table 1. Baseline Characteristics of the Study Population

Supporting image 2

Table 2. Incidence rates for hip fracture and major osteoporotic fracture, overall and by RA disease activity level category

Supporting image 3

Figure 1. Incidence rate ratios for hip fracture and major osteoporotic fracture by RA disease activity level


Disclosures: R. Elam: None; E. Kersey: None; J. Li: None; G. Schmajuk: None; L. Carbone: None.

To cite this abstract in AMA style:

Elam R, Kersey E, Li J, Schmajuk G, Carbone L. Fracture Incidence Rates in Persons with Rheumatoid Arthritis by Disease Activity Level [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/fracture-incidence-rates-in-persons-with-rheumatoid-arthritis-by-disease-activity-level/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fracture-incidence-rates-in-persons-with-rheumatoid-arthritis-by-disease-activity-level/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology